Klinische studies myelofibrose

Onbehandelde patiënten

KRT-232-115 

A phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

• Principal investigator: Prof. Dr. Timothy Devos
• More information: NCT06479135
• Internal reference number: S69074

Behandelde patiënten

BBI-TP-3654-102

A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis

• Principal investigator: Prof. Dr. Timothy Devos
• More information: NCT04176198
• Internal reference number: S67654